B.R.A.I.N. Biotechnology Research and Information Network (BNN) AI Stock Analysis

• Market Cap: €55.49M
• Dividend Yield: N/A
• Average Volume (3M): 10.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.11
• Revenue Growth: -4.90%
• EPS Growth: -69.80%
• Country: DE
• Employees: 296
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 21,847,494
• 10 Day Avg. Volume: 22,707
• 30 Day Avg. Volume: 10,926
• PEG Ratio: -0.69
• Price to Book (P/B): 25.87
• Price to Sales (P/S): 0.96
• P/FCF Ratio: -4.42
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €5.00
• Price Target Upside: 96.85% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.29
• Revenue Forecast (FY): €55.62M

• Rating: 46 Neutral
• Price Target: €2.50 ▼(-1.57% Downside)
• Action: Upgraded Date: 02/27/26
• Date: Action: Upgraded 02/27/26

The score is primarily held down by weak financial performance—persistent losses, consistent cash burn, declining revenue, and a notably weakened 2025 balance sheet with higher leverage. Technical indicators provide a modest offset with price trading above key moving averages and neutral-to-positive momentum, while valuation remains unattractive/limited due to negative earnings and no dividend data.

Positive Factors

Gross margin improvement

An improved gross margin in 2025 indicates the business has regained some product-level economics via pricing, mix or cost control. Over the next 2–6 months sustained improvement could provide operating leverage potential, making progress toward scalable profitability if maintained.

Free cash flow improvement

Less-negative free cash flow in 2025 shows management made measurable progress toward cash efficiency. If this trend continues it reduces near-term external funding needs and the pace of dilution, improving the company’s ability to self-fund development and sustain operations longer-term.

Operational scale (R&D capacity)

A headcount of ~296 supports meaningful R&D and operational capability for a biotech developer. This scale enables parallel programs, institutional knowledge retention, and the capacity to advance pipelines or commercial initiatives, which are durable advantages versus smaller, resource-constrained peers.

Negative Factors

Persistent unprofitability

Ongoing net losses are a structural weakness that erodes equity and restricts reinvestment. Persistent unprofitability increases reliance on capital markets, raises dilution risk, and undermines long-term return prospects unless operating margins materially improve and losses narrow sustainably.

Chronic cash burn

Consistent negative operating and free cash flow indicate the business consumes cash rather than funds itself. This chronic burn forces repeated external financing, heightens refinancing and dilution risk, and constrains strategic execution and long-term investment in R&D or commercialization.

Weakened balance sheet & leverage

A materially weaker 2025 balance sheet and higher leverage reduce financial flexibility. Elevated debt-to-equity increases refinancing risk and limits ability to absorb setbacks or invest in growth, making the company more vulnerable if operating performance does not improve soon.

B.R.A.I.N. Biotechnology Research and Information Network Business Overview & Revenue Model

Company Description

BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical industries in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates in two segments, BioScience and BioIndustrial. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and nature-based active ingredients for product development in the food, animal feed, skin care, cosmetics, and chemical industries. The company also identifies and develops optimized enzymes and biocatalysts for the production of food and beverages, and wound care preparations or lubricants, as well as for starch processing of bioethanol production; and microorganisms as the functional biomass for optimized industrial production processes, recycling of greenhouse gas CO2 as an industrial raw material, and extraction of precious and rare earth metals. It has strategic partnerships with AnalytiCon Discovery GmbH and Roquette to develop natural sweeteners and sweet taste enhancers. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.

How the Company Makes Money

BNN generates revenue through multiple streams, including consultancy fees for research services provided to academic institutions and corporate clients, subscription fees for access to its proprietary databases and research findings, and licensing agreements for its patented technologies and products. Additionally, BNN collaborates with pharmaceutical companies and agricultural firms in joint research projects, which often include funding and investment from these partners. Strategic partnerships with universities and research institutions also contribute to funding through grants and collaborative projects, enhancing BNN's financial stability and growth potential.

B.R.A.I.N. Biotechnology Research and Information Network Financial Statement Overview

Summary

Financials indicate elevated risk: persistent net losses, negative operating profitability, and ongoing cash burn (negative operating and free cash flow in all years). Revenue declined in 2024 and again in 2025, and the balance sheet weakened materially in 2025 with higher leverage due to sharply lower equity, increasing refinancing/dilution risk despite modest gross margin and free-cash-flow improvement in 2025.

Income Statement

The company remains structurally unprofitable: net losses persist across all reported years, with negative operating profitability and negative net margins. Revenue has also turned weaker recently, declining in 2024 and again in 2025. A positive is that gross margin improved in 2025 versus 2024, but it remains low relative to prior years and has not translated into improved bottom-line performance.

Balance Sheet

Balance sheet risk has risen sharply. Debt is high relative to equity in 2025, driven by a steep drop in equity versus 2024, which materially increases financial leverage and reduces flexibility. Returns on equity are deeply negative, reflecting ongoing losses and a weakened capital base; this creates higher refinancing/dilution risk if losses persist.

Cash Flow

Cash generation is weak, with negative operating cash flow and negative free cash flow in every year shown, indicating the business is consuming cash rather than funding itself. Free cash flow improved in 2025 versus 2024 (less negative), but operating cash flow worsened meaningfully, highlighting continued dependence on external capital to support operations.

Breakdown	Sep 2025	Dec 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	49.62M	54.63M	55.34M	49.51M	38.39M
Gross Profit	2.01M	401.00K	3.47M	1.43M	-1.95M
EBITDA	-4.17M	-4.23M	-1.98M	-1.30M	2.01M
Net Income	-11.74M	-11.13M	-8.28M	-6.59M	-4.97M
Balance Sheet
Total Assets	66.34M	88.74M	70.94M	77.99M	77.74M
Cash, Cash Equivalents and Short-Term Investments	6.32M	27.29M	5.41M	8.53M	24.65M
Total Debt	24.03M	29.82M	25.32M	10.74M	2.64M
Total Liabilities	64.50M	74.85M	47.92M	43.74M	35.91M
Stockholders Equity	1.84M	12.62M	21.77M	29.64M	38.78M
Cash Flow
Free Cash Flow	-10.76M	-5.31M	-6.86M	-7.57M	-5.17M
Operating Cash Flow	-9.23M	-3.58M	-4.22M	-1.49M	-3.91M
Investing Cash Flow	-1.56M	-1.69M	562.00K	-12.69M	-2.18M
Financing Cash Flow	-10.14M	26.99M	459.00K	-1.97M	11.57M

B.R.A.I.N. Biotechnology Research and Information Network Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.54
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BNN, the sentiment is Positive. The current price of 2.54 is above the 20-day moving average (MA) of 2.28, above the 50-day MA of 2.42, and above the 200-day MA of 2.30, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 57.54 is Neutral, neither overbought nor oversold. The STOCH value of 62.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:BNN.

B.R.A.I.N. Biotechnology Research and Information Network Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GME	60 Neutral	€14.86M	8.38	8.35%	3.46%	-23.48%	―
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
BNN	46 Neutral	€55.49M	-4.73	-111.86%	―	-4.90%	-69.80%
HPHA	42 Neutral	€140.82M	-5.37	-112.95%	―	-64.15%	-39.31%